Athira Pharma Announces Exclusive License to Lasofoxifene Ph 3 Development Program for Metastatic Breast Cancer Candidate and Financing for up to $236M December 22, 2025
Preliminary Analysis Shows 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01 December 22, 2025
IND Application to Initiate a Ph 1 Trial of ABP-102/CT-P72 for HER2-positive Cancers submitted to the US FDA December 22, 2025
DATROWAY® Type II Variation Application Validated in the EU for Patients with 1L Metastatic, IO-ineligible TNBC December 22, 2025
ENHERTU Plus Pertuzumab Approved in the US for Patients with 1L HER2 Positive Metastatic Breast Cancer December 22, 2025
Pan Cancer T Secures EUR 10M to Advance First-in-Human Trial of PCT1:CO-STIM in TNBC December 15, 2025
Updated Efficacy Data of Ivonescimab Combined with Chemo as 1L Treatment for TNBC Presented December 15, 2025
Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of Eftilagimod Alfa December 9, 2025
Pan Cancer T Secures EUR 10 Million to Advance First-in-Human Trial of Novel TCR-T Cell Therapy for TNBC December 9, 2025
Additional Positive LP-184 Ph 1a Results Reported Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients December 9, 2025
No median OS difference observed in TNBC patients treated with nadunolimab + gemcitabine/carboplatin (GC) vs GC in Ph 1b/2 TRIFOUR study December 9, 2025
Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum Announced December 9, 2025
Gedatolisib NDA submission to FDA in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer completed November 24, 2025
Artios Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs in Indications of High Unmet Need November 24, 2025
FAILED TRIAL: Ph 3 ASCENT-07 study of Trodelvy® (sacituzumab govitecan-hziy) vs chemo in 1L HR+/HER2-neg metastatic breast cancer patients did not meet the primary endpoint of PFS November 10, 2025
